Researchers at the University of North Carolina – Chapel Hill, in collaboration with Electromedical Products International, Inc. (EPI), have developed a groundbreaking non-invasive brain stimulation technology that shows great promise in treating depression. A recent clinical trial published in the American Journal of Psychiatry revealed a significant reduction in symptoms of major depressive disorder in patients who participated in the study.
The technology works by delivering personalized brain stimulation based on real-time measurements of brain activity, targeting specific electric activity patterns associated with depression. This approach resulted in an impressive 80% of patients being free of clinical depression symptoms just two weeks after completing the treatment.
Dr. Flavio Frohlich, Professor of Psychiatry at UNC – Chapel Hill, described the results as “stunning” and potentially a “game changer” for millions of patients seeking better treatment options for their depression symptoms. The success of the treatment was attributed to the modulation of targeted electric brain activity, which was closely linked to symptom reduction.
EPI’s device adjusts the electric waveform delivered to the patient during each session based on the brain’s response to the stimulation. This technology was likened to engaging in a dialogue with the brain by Dr. Frohlich, who chairs EPI’s Scientific Advisory Board.
The study’s findings have paved the way for a double-blind, placebo-controlled study of this technology, as researchers and EPI executives are eager to move forward with the potential market impact of this innovative treatment. EPI is a leading neuromodulation therapeutic company specializing in non-invasive brain stimulation for psychiatric disorders and insomnia, along with microcurrent therapy for pain management.
Source
Photo credit www.biospace.com
